Please use this identifier to cite or link to this item: https://scholarbank.nus.edu.sg/handle/10635/120799
DC FieldValue
dc.titleProperties of activated microglia and pharmacologic interference by propentofylline
dc.contributor.authorMcRae, A.
dc.contributor.authorLing, E.-A.
dc.contributor.authorSchubert, P.
dc.contributor.authorRudolphi, K.
dc.date.accessioned2015-09-09T07:03:59Z
dc.date.available2015-09-09T07:03:59Z
dc.date.issued1998
dc.identifier.citationMcRae, A.,Ling, E.-A.,Schubert, P.,Rudolphi, K. (1998). Properties of activated microglia and pharmacologic interference by propentofylline. Alzheimer Disease and Associated Disorders 12 (SUPPL. 2) : S15-S20. ScholarBank@NUS Repository.
dc.identifier.issn08930341
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/120799
dc.description.abstractAmeboid microglia are activated macrophages in the developing brain. With age, these cells undergo gradual transformation into the adult form, known as ramified or resting microglia. In response to neuronal insults, microglia change their morphology and immunophenotype and proliferate to become full-blown brain macrophages. Microglia release a battery of neurotoxic substances. Responses to neuronal damage occur at various intervals after the insult, suggesting that microglia may be an attractive target for pharmacologic intervention. The cerebrospinal fluid (CSF) of Alzheimer disease (AD) patients contains antibodies that recognize activated microglia in the developing rat and in the ischemic gerbil brain. These results suggest that AD shares common mechanisms related to the activation of microglia with both these experimental models. In vitro, the xanthine derivative propentofylline (PPF) depresses the production of reactive oxygen intermediates produced by macrophages. To appreciate in vivo interactions of PPF, two models were employed: developing rats and adult gerbils exposed to ischemia. Newborn rats were administered PPF (10 mg/kg) for 7 days. Gerbils were exposed to 5 min of transient forebrain ischemia and received PPF (10 mg/kg) 24 h later until the day before sacrifice. Animals were sacrificed at 7 or 14 days after reperfusion. Brains were processed for immunocytochemistry. Reactive microglia were visualized with monoclonal antibodies OX18 and OX42 or AD-CSF microglia antibodies. In the case of ischemia, an antibody against the amyloid precursor protein (APP) (residues 676-695) was included. Newborn rats receiving PPF for 7 days displayed a dramatic reduction in the number of activated microglia compared with untreated littermates. Ischemic control in gerbils showed complete nerve death, accumulations of APP, and enhanced microglial reactivity. In gerbils receiving PPF, APP accumulation was absent or very slight, and activated microglia were downregulated. The ability of PPF to interfere with activated microglia suggests that this agent may be useful for slowing progressive nerve cell death associated with AD, which is considered to be largely influenced by pathologic glial reactions.
dc.sourceScopus
dc.subjectAmyloid
dc.subjectAstroglia
dc.subjectDementing disorders
dc.subjectMicroglia
dc.subjectNeuroprotection
dc.typeConference Paper
dc.contributor.departmentANATOMY
dc.description.sourcetitleAlzheimer Disease and Associated Disorders
dc.description.volume12
dc.description.issueSUPPL. 2
dc.description.pageS15-S20
dc.description.codenADADE
dc.identifier.isiutNOT_IN_WOS
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.